Identification

Name
Clobetasol propionate
Accession Number
DB01013  (APRD00876)
Type
Small Molecule
Groups
Approved
Description

A derivative of prednisolone with high glucocorticoid activity and low mineralocorticoid activity. Absorbed through the skin faster than fluocinonide, it is used topically in treatment of psoriasis but may cause marked adrenocortical suppression.

Structure
Thumb
Synonyms
  • 21-chloro-9-fluoro-11β,17-dihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17-propionate
  • clobetasol 17-propanoate
  • clobetasol 17-propionate
  • Clobetasol propionate E
External IDs
CCI 4725 / CCI-4725 / GR 2/925 / GR-2/925
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clobetasol Cream 0.05%Cream0.05 %TopicalPrempharm Inc1996-12-232005-08-05Canada
Clobetasol Ointment 0.05%Ointment0.05 %TopicalPrempharm Inc1996-12-232005-08-05Canada
Clobetasol PropionateAerosol, foam.5 mg/gTopicalPhysicians Total Care, Inc.2011-08-16Not applicableUs
Clobetasol PropionateAerosol, foam.5 mg/gTopicalPrasco, Laboratories2010-01-152016-03-04Us
Clobetasol Scalp Application 0.05%Ointment0.05 %TopicalPrempharm Inc1996-12-232005-08-05Canada
ClobexLotion.05 g/100mLTopicalGalderma2003-08-01Not applicableUs
ClobexLotion.05 mL/100mLTopicalPhysicians Total Care, Inc.2006-08-16Not applicableUs
ClobexShampoo.05 g/100mLTopicalGalderma2004-03-01Not applicableUs
ClobexSpray.5 mg/mLTopicalPhysicians Total Care, Inc.2006-01-23Not applicableUs
ClobexSpray.05 g/mLTopicalGalderma2005-10-27Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-clobetasol Propionate Cream 0.05%Cream.05 %TopicalAltimed Pharma Inc.1993-12-312001-09-05Canada
Alti-clobetasol Propionate Ont 0.05%Ointment.05 %TopicalAltimed Pharma Inc.1993-12-312001-09-05Canada
Alti-clobetasol Propionate Scalp Application 0.05%Liquid.05 %TopicalAltimed Pharma Inc.1993-12-312001-09-05Canada
Clobetasol PropionateShampoo.05 g/100mLTopicalPerrigo New York Inc.2012-08-10Not applicableUs
Clobetasol PropionateCream.5 mg/gTopicalA S Medication Solutions2014-02-032017-06-20Us
Clobetasol PropionateOintment.5 mg/gTopicalHi Tech Pharmacal Co., Inc.2010-06-07Not applicableUs
Clobetasol PropionateSpray.05 g/mLTopicalZydus Pharmaceuticals Usa, Inc.2017-07-12Not applicableUs
Clobetasol PropionateOintment.5 mg/gTopicalMylan Pharmaceuticals2017-09-13Not applicableUs
Clobetasol PropionateSolution.5 mg/mLTopicalTaro Pharmaceuticals U.S.A., Inc.1998-11-16Not applicableUs
Clobetasol PropionateOintment.5 mg/gTopicalA S Medication Solutions1996-02-23Not applicableUs
International/Other Brands
Clobesol (GlaxoSmithKline) / Dermovate (GlaxoSmithKline) / Embeline (Hi-Tech) / Embeline E (Hi-Tech)
Categories
UNII
779619577M
CAS number
25122-46-7
Weight
Average: 466.97
Monoisotopic: 466.192230046
Chemical Formula
C25H32ClFO5
InChI Key
CBGUOGMQLZIXBE-XGQKBEPLSA-N
InChI
InChI=1S/C25H32ClFO5/c1-5-21(31)32-25(20(30)13-26)14(2)10-18-17-7-6-15-11-16(28)8-9-22(15,3)24(17,27)19(29)12-23(18,25)4/h8-9,11,14,17-19,29H,5-7,10,12-13H2,1-4H3/t14-,17-,18-,19-,22-,23-,24-,25-/m0/s1
IUPAC Name
(1R,2S,10S,11S,13S,14R,15S,17S)-14-(2-chloroacetyl)-1-fluoro-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-14-yl propanoate
SMILES

Pharmacology

Indication

For short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp.

Structured Indications
Pharmacodynamics

Like other topical corticosteroids, clobetasol has anti-inflammatory, antipruritic, and vasoconstrictive properties. It is a very high potency topical corticosteroid that should not be used with occlusive dressings. It is recommended that treatment should be limited to 2 consecutive weeks and therapy should be discontinued when adequate results have been achieved.

Mechanism of action

The precise mechanism of the antiinflammatory activity of topical steroids in the treatment of steroid-responsive dermatoses, in general, is uncertain. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Initially, however, clobetasol, like other corticosteroids, bind to the glucocorticoid receptor, which complexes, enteres the cell nucleus and modifies genetic transcription (transrepression/transactivation).

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
Absorption

Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Metabolized, primarily in the liver, and then excreted by the kidneys.

Route of elimination

Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids, including clobetasol propionate and its metabolites, are also excreted into the bile.

Half life
Not Available
Clearance
Not Available
Toxicity

Oral LD50 in rat and mouse is >3000 mg/kg. Topically applied clobetasol can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose include thinning of skin and suppression of adrenal cortex (decreased ability to respond to stress).

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Clobetasol propionate.Investigational
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Clobetasol propionate.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Clobetasol propionate.Approved, Experimental, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Clobetasol propionate.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Clobetasol propionate.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Clobetasol propionate.Approved, Withdrawn
AldesleukinClobetasol propionate may decrease the antineoplastic activities of Aldesleukin.Approved
AlmasilateThe bioavailability of Clobetasol propionate can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Clobetasol propionate.Experimental
AloglutamolThe bioavailability of Clobetasol propionate can be decreased when combined with Aloglutamol.Approved
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Clobetasol propionate.Experimental
AluminiumThe bioavailability of Clobetasol propionate can be decreased when combined with Aluminium.Approved, Investigational
Aluminium acetoacetateThe bioavailability of Clobetasol propionate can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Clobetasol propionate can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Clobetasol propionate can be decreased when combined with Aluminum hydroxide.Approved, Investigational
AmbenoniumThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Clobetasol propionate.Approved
AmiodaroneThe serum concentration of Clobetasol propionate can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BClobetasol propionate may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Clobetasol propionate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Clobetasol propionate.Investigational
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Anthrax immune globulin human.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Clobetasol propionate.Approved, Investigational
ApalutamideThe serum concentration of Clobetasol propionate can be decreased when it is combined with Apalutamide.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Clobetasol propionate.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Clobetasol propionate.Approved, Investigational
AprepitantThe serum concentration of Clobetasol propionate can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Clobetasol propionate can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Clobetasol propionate.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Clobetasol propionate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Clobetasol propionate.Approved
AzosemideClobetasol propionate may increase the hypokalemic activities of Azosemide.Investigational
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Clobetasol propionate.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Clobetasol propionate.Experimental
BendroflumethiazideClobetasol propionate may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Clobetasol propionate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Clobetasol propionate.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Clobetasol propionate.Approved, Investigational
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Clobetasol propionate.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Clobetasol propionate.Experimental
Bismuth SubcitrateThe bioavailability of Clobetasol propionate can be decreased when combined with Bismuth Subcitrate.Approved, Investigational
Bismuth subnitrateThe bioavailability of Clobetasol propionate can be decreased when combined with Bismuth subnitrate.Approved, Experimental
BoceprevirThe serum concentration of Clobetasol propionate can be increased when it is combined with Boceprevir.Approved, Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Clobetasol propionate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Clobetasol propionate.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Clobetasol propionate.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Clobetasol propionate.Experimental
BumetanideClobetasol propionate may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Clobetasol propionate.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Clobetasol propionate can be decreased when combined with Calcium Carbonate.Approved, Investigational
Calcium silicateThe bioavailability of Clobetasol propionate can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideClobetasol propionate may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of Clobetasol propionate can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Clobetasol propionate.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Clobetasol propionate.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Clobetasol propionate.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Clobetasol propionate.Approved, Investigational
CeritinibClobetasol propionate may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Clobetasol propionate.Approved, Investigational, Vet Approved
ChlorothiazideClobetasol propionate may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Clobetasol propionate can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneClobetasol propionate may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Clobetasol propionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Clobetasol propionate.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Clobetasol propionate can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Clobetasol propionate.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of Clobetasol propionate can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Clobetasol propionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Clobetasol propionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Clobetasol propionate can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Clobetasol propionate.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Clobetasol propionate.Approved, Investigational
CyclopenthiazideClobetasol propionate may increase the hypokalemic activities of Cyclopenthiazide.Experimental
DaidzeinThe serum concentration of Clobetasol propionate can be increased when it is combined with Daidzein.Experimental
DanazolClobetasol propionate may increase the fluid retaining activities of Danazol.Approved
DarunavirThe serum concentration of Clobetasol propionate can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Demecarium.Approved
DersalazineThe risk or severity of adverse effects can be increased when Dersalazine is combined with Clobetasol propionate.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Clobetasol propionate.Approved, Vet Approved
DienestrolThe serum concentration of Clobetasol propionate can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Clobetasol propionate can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Clobetasol propionate.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clobetasol propionate.Approved, Investigational
DistigmineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Clobetasol propionate.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Clobetasol propionate.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Clobetasol propionate.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Clobetasol propionate can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Clobetasol propionate can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Clobetasol propionate.Approved
EpitizideClobetasol propionate may increase the hypokalemic activities of Epitizide.Experimental
EquolThe serum concentration of Clobetasol propionate can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of Clobetasol propionate can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Clobetasol propionate can be increased when it is combined with Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Clobetasol propionate can be increased when it is combined with Estradiol valerate.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Clobetasol propionate can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Clobetasol propionate can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Clobetasol propionate can be increased when it is combined with Estrone.Approved
Etacrynic acidClobetasol propionate may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Clobetasol propionate.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Clobetasol propionate.Experimental
Ethinyl EstradiolThe serum concentration of Clobetasol propionate can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Clobetasol propionate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Clobetasol propionate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Clobetasol propionate.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Clobetasol propionate.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Clobetasol propionate.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Clobetasol propionate.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Clobetasol propionate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Clobetasol propionate.Approved
FenthionThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Clobetasol propionate.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Clobetasol propionate.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Clobetasol propionate.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Clobetasol propionate.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Clobetasol propionate.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Clobetasol propionate.Experimental
FluoxymesteroneClobetasol propionate may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Clobetasol propionate.Approved, Investigational
FosaprepitantThe serum concentration of Clobetasol propionate can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Clobetasol propionate can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FurosemideClobetasol propionate may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Clobetasol propionate can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with GI-5005.Investigational
GLPG-0492Clobetasol propionate may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Clobetasol propionate.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Clobetasol propionate.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Clobetasol propionate.Experimental
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexestrolThe serum concentration of Clobetasol propionate can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Clobetasol propionate.Investigational
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Human rabies virus immune globulin.Approved
Huperzine AThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Huperzine A.Approved, Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Clobetasol propionate.Approved, Investigational
HydrochlorothiazideClobetasol propionate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideClobetasol propionate may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Clobetasol propionate can be decreased when combined with Hydrotalcite.Approved, Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Clobetasol propionate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Clobetasol propionate.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Clobetasol propionate.Approved, Investigational
IdelalisibThe serum concentration of Clobetasol propionate can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Clobetasol propionate.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Clobetasol propionate.Approved
IndapamideClobetasol propionate may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Clobetasol propionate can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Clobetasol propionate.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Clobetasol propionate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Clobetasol propionate.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Clobetasol propionate.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Clobetasol propionate.Withdrawn
ItraconazoleThe serum concentration of Clobetasol propionate can be increased when it is combined with Itraconazole.Approved, Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Clobetasol propionate.Experimental
KetoconazoleThe serum concentration of Clobetasol propionate can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Clobetasol propionate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Clobetasol propionate.Approved
LacidipineThe serum concentration of Lacidipine can be decreased when it is combined with Clobetasol propionate.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Clobetasol propionate.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Clobetasol propionate.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Clobetasol propionate.Experimental
LopinavirThe serum concentration of Clobetasol propionate can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Clobetasol propionate.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Clobetasol propionate.Approved, Investigational
LumacaftorThe serum concentration of Clobetasol propionate can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Clobetasol propionate.Approved, Investigational
MagaldrateThe bioavailability of Clobetasol propionate can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium hydroxideThe bioavailability of Clobetasol propionate can be decreased when combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe bioavailability of Clobetasol propionate can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Clobetasol propionate can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Clobetasol propionate.Approved
Magnesium silicateThe bioavailability of Clobetasol propionate can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of Clobetasol propionate can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Clobetasol propionate.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clobetasol propionate.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Clobetasol propionate.Approved
MefloquineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Mefloquine.Approved, Investigational
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Clobetasol propionate.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Clobetasol propionate.Approved
MesteroloneClobetasol propionate may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Clobetasol propionate can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Clobetasol propionate.Approved, Investigational, Withdrawn
MethallenestrilThe serum concentration of Clobetasol propionate can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideClobetasol propionate may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Clobetasol propionate.Approved, Vet Approved
MethyltestosteroneClobetasol propionate may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Metoclopramide.Approved, Investigational
MetolazoneClobetasol propionate may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Clobetasol propionate can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Minaprine.Approved
MitotaneThe serum concentration of Clobetasol propionate can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Clobetasol propionate.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Clobetasol propionate.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Clobetasol propionate.Experimental
MoxestrolThe serum concentration of Clobetasol propionate can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Clobetasol propionate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clobetasol propionate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Clobetasol propionate.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Clobetasol propionate.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Clobetasol propionate.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Nalidixic Acid.Approved, Investigational
NandroloneClobetasol propionate may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoateClobetasol propionate may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Clobetasol propionate.Approved, Vet Approved
NefazodoneThe serum concentration of Clobetasol propionate can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Clobetasol propionate can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Clobetasol propionate.Approved, Investigational
NevirapineThe serum concentration of Clobetasol propionate can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Clobetasol propionate.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Clobetasol propionate.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Clobetasol propionate.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Clobetasol propionate.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Norfloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clobetasol propionate.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Clobetasol propionate.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Clobetasol propionate.Vet Approved
OxandroloneClobetasol propionate may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Clobetasol propionate.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Oxolinic acid.Experimental
OxymetholoneClobetasol propionate may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clobetasol propionate.Approved, Withdrawn
ParaoxonThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Clobetasol propionate.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Clobetasol propionate.Approved, Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Clobetasol propionate can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PhenobarbitalThe serum concentration of Clobetasol propionate can be decreased when it is combined with Phenobarbital.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Clobetasol propionate.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Clobetasol propionate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Clobetasol propionate.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Clobetasol propionate.Approved, Investigational
PhenytoinThe serum concentration of Clobetasol propionate can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Physostigmine.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clobetasol propionate.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Pipemidic acid.Experimental
PiretanideClobetasol propionate may increase the hypokalemic activities of Piretanide.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Clobetasol propionate.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clobetasol propionate.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Clobetasol propionate.Experimental
Polyestradiol phosphateThe serum concentration of Clobetasol propionate can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideClobetasol propionate may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Clobetasol propionate can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Clobetasol propionate.Experimental, Investigational
PrimidoneThe serum concentration of Clobetasol propionate can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Clobetasol propionate.Experimental
PromestrieneThe serum concentration of Clobetasol propionate can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Clobetasol propionate.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Clobetasol propionate.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Clobetasol propionate.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Clobetasol propionate.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Pyridostigmine.Approved, Investigational
QuinestrolThe serum concentration of Clobetasol propionate can be increased when it is combined with Quinestrol.Approved
QuinethazoneClobetasol propionate may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Rabies virus inactivated antigen, A.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Clobetasol propionate.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clobetasol propionate.Approved, Experimental, Investigational
RifabutinThe serum concentration of Clobetasol propionate can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Clobetasol propionate can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Clobetasol propionate can be decreased when it is combined with Rifapentine.Approved, Investigational
RindopepimutThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Rindopepimut.Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Clobetasol propionate.Approved, Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Rubella virus vaccine.Approved, Investigational
RufloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Clobetasol propionate.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Clobetasol propionate.Approved, Investigational, Vet Approved
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Clobetasol propionate.Approved
SaquinavirThe serum concentration of Clobetasol propionate can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Clobetasol propionate can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Clobetasol propionate.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Clobetasol propionate.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Clobetasol propionate.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Sitafloxacin.Experimental, Investigational
Sodium bicarbonateThe bioavailability of Clobetasol propionate can be decreased when combined with Sodium bicarbonate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Clobetasol propionate.Investigational
St. John's WortThe serum concentration of Clobetasol propionate can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneClobetasol propionate may increase the fluid retaining activities of Stanolone.Illicit, Investigational
StanozololClobetasol propionate may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Clobetasol propionate can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Clobetasol propionate.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Clobetasol propionate.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Clobetasol propionate.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Clobetasol propionate.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Clobetasol propionate can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Clobetasol propionate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Tacrine.Investigational, Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Clobetasol propionate.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Clobetasol propionate.Approved, Withdrawn
TelithromycinThe serum concentration of Clobetasol propionate can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Clobetasol propionate.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Clobetasol propionate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Clobetasol propionate.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Clobetasol propionate.Approved
TestosteroneClobetasol propionate may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone cypionateClobetasol propionate may increase the fluid retaining activities of Testosterone cypionate.Approved
Testosterone enanthateClobetasol propionate may increase the fluid retaining activities of Testosterone enanthate.Approved
Testosterone propionateClobetasol propionate may increase the fluid retaining activities of Testosterone propionate.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateClobetasol propionate may increase the fluid retaining activities of Testosterone undecanoate.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Clobetasol propionate.Approved
TiboloneThe serum concentration of Clobetasol propionate can be increased when it is combined with Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Clobetasol propionate.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Clobetasol propionate.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Clobetasol propionate.Approved
TorasemideClobetasol propionate may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Clobetasol propionate.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Clobetasol propionate.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Trichlorfon.Vet Approved
TrichlormethiazideClobetasol propionate may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Clobetasol propionate.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Clobetasol propionate.Approved
TromethamineThe bioavailability of Clobetasol propionate can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Clobetasol propionate.Approved, Investigational, Withdrawn
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VoriconazoleThe serum concentration of Clobetasol propionate can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinClobetasol propionate may increase the anticoagulant activities of Warfarin.Approved
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Yellow Fever Vaccine.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clobetasol propionate.Approved, Investigational
ZeranolThe serum concentration of Clobetasol propionate can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Clobetasol propionate.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Clobetasol propionate.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Elks, J., Phillipps, G.H. and May, P.J.; US. Patent 3,721,687; March 20, 1973; assigned to Glaxo Laboratories Limited, England.

General References
Not Available
External Links
KEGG Drug
D01272
PubChem Compound
32798
PubChem Substance
46505670
ChemSpider
30399
BindingDB
39347
ChEBI
31414
ChEMBL
CHEMBL1159650
Therapeutic Targets Database
DAP001183
PharmGKB
PA164744375
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Clobetasol_propionate
AHFS Codes
  • 84:06.00 — Anti-inflammatory Agents
FDA label
Download (95.3 KB)
MSDS
Download (74.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedOtherAtopic Dermatitis (AD)1
1CompletedOtherPsoriasis1
1CompletedTreatmentAtopic Dermatitis (AD)1
1CompletedTreatmentPsoriasis Vulgaris2
1TerminatedOtherPsoriasis1
2Active Not RecruitingTreatmentColon Adenocarcinoma / Rectal Adenocarcinoma / Stage III Colorectal Cancer / Stage III Colorectal Cancer AJCC v7 / Stage IIIA Colorectal Cancer / Stage IIIA Colorectal Cancer AJCC v7 / Stage IIIB Colorectal Cancer / Stage IIIB Colorectal Cancer AJCC v7 / Stage IIIC Colorectal Cancer / Stage IIIC Colorectal Cancer AJCC v7 / Stage IV Colorectal Cancer / Stage IV Colorectal Cancer AJCC v7 / Stage IVA Colorectal Cancer / Stage IVA Colorectal Cancer AJCC v7 / Stage IVB Colorectal Cancer / Stage IVB Colorectal Cancer AJCC v71
2CompletedTreatmentVulvar Lichen Sclerosus1
2RecruitingTreatmentOral Lichen Planus2
2TerminatedTreatmentVulvar Lichen Sclerosus1
3CompletedTreatmentAlopecia Areata (AA)1
3CompletedTreatmentChronic Stable Plaque Psoriasis1
3CompletedTreatmentPsoriasis2
3CompletedTreatmentScalp Psoriasis1
4CompletedNot AvailablePsoriasis1
4CompletedTreatmentChronic Stable Plaque Psoriasis1
4CompletedTreatmentDermatitis, Chronic1
4CompletedTreatmentHand Dermatosis1
4CompletedTreatmentHypertrophic Scars1
4CompletedTreatmentPlaque Psoriasis4
4CompletedTreatmentPlaque-Type Psoriasis1
4CompletedTreatmentPsoriasis3
4CompletedTreatmentPsoriatic Nails1
4CompletedTreatmentScalp Psoriasis1
4RecruitingPreventionBullous Pemphigoid (BP)1
4Unknown StatusTreatmentDermatitis, Contact / Dermatitis, Occupational1
4Unknown StatusTreatmentHair Thinning1
Not AvailableCompletedTreatmentVulvar Lichen Sclerosus1
Not AvailableTerminatedNot AvailablePsoriasis1

Pharmacoeconomics

Manufacturers
  • Perrigo israel pharmaceuticals ltd
  • Connetics corp
  • Stiefel laboratories inc
  • Actavis mid atlantic llc
  • E fougera div altana inc
  • Taro pharmaceuticals inc
  • Teva pharmaceuticals usa
  • Altana inc
  • Stiefel a gsk co
  • Taro pharmaceuticals usa inc
  • Hi tech pharmacal co inc
  • Perrigo co
  • Galderma laboratories l p
  • Nycomed us inc
  • Galderma laboratories inc
  • Tolmar inc
  • Wockhardt eu operations (swiss) ag
  • Galderma laboratories lp
Packagers
  • Accra Pac Inc.
  • Ameri-Pac Inc.
  • A-S Medication Solutions LLC
  • Contract Pharm
  • Dermalogix
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • DPT Laboratories Ltd.
  • E. Fougera and Co.
  • Galderma Laboratories
  • GlaxoSmithKline Inc.
  • Glenmark Generics Ltd.
  • Hi Tech Pharmacal Co. Inc.
  • Inyx Usa Ltd.
  • Nycomed Inc.
  • Palmetto Pharmaceuticals Inc.
  • Perrigo Co.
  • Pharma Pac LLC
  • Pharmaderm
  • Pharmedix
  • Physicians Total Care Inc.
  • Prasco Labs
  • Preferred Pharmaceuticals Inc.
  • Quality Care
  • Rebel Distributors Corp.
  • Stat Rx Usa
  • Stiefel Labs
  • Taro Pharmaceuticals USA
  • Teva Pharmaceutical Industries Ltd.
  • Watson Pharmaceuticals
  • Wockhardt Ltd.
Dosage forms
FormRouteStrength
LiquidTopical.05 %
EmulsionTopical.5 mg/g
GelTopical.05 mg/g
GelTopical.5 mg/g
LotionTopical.05 mg/100mL
LotionTopical.5 mg/mL
ShampooTopical.05 g/100mL
SolutionTopical.462 mg/mL
SolutionTopical.4625 mg/mL
SprayTopical.05 g/mL
LotionTopical.05 mL/100mL
LotionTopical.05 g/100mL
SprayTopical.5 mg/mL
ShampooTopical0.05 %
SprayTopical0.05 %
ShampooTopical.5 mg/mL
Kit
SolutionTopical.05 %
CreamTopical.25 mg/g
CreamTopical0.05 %
OintmentTopical0.05 %
LotionTopical0.05 %
CreamTopical.05 %
OintmentTopical.05 %
Aerosol, foamTopical.5 mg/g
Aerosol, foamTopical0.05 %
SolutionTopical0.05 %
CreamTopical.5 mg/g
OintmentTopical.5 mg/g
SolutionTopical.5 mg/mL
Prices
Unit descriptionCostUnit
Clobex 0.05% Lotion 118ml Bottle513.56USD bottle
Clobex Spray 0.05% Liquid 125ml Bottle501.7USD bottle
Olux 0.05% Foam 100 gm Can443.77USD can
Olux-E 0.05% Foam 100 gm Can384.32USD can
Olux Olux-E Complete Pack 0.05 & 0.05% Miscellaneous 110 gm Can373.65USD can
Clobex 0.05% Shampoo 118ml Bottle365.67USD bottle
Clobetasol Propionate 0.05% Foam 100 gm Can326.37USD can
Clobex 0.05% Lotion 59ml Bottle280.8USD bottle
Clobex Spray 0.05% Liquid 59ml Bottle278.93USD bottle
Olux 0.05% Foam 50 gm Can239.07USD can
Temovate 0.05% Cream 60 gm Tube234.19USD tube
Temovate 0.05% Gel 60 gm Tube234.19USD tube
Temovate E 0.05% Cream 60 gm Tube234.19USD tube
Clobetasol Propionate 0.05% Foam 50 gm Can177.05USD can
Temovate 0.05% Ointment 30 gm Tube132.55USD tube
Temovate 0.05% Solution 50ml Bottle113.82USD bottle
Temovate 0.05% Cream 45 gm Tube95.43USD tube
Clobetasol Propionate 0.05% Gel 60 gm Tube93.82USD tube
Temovate 0.05% Ointment 15 gm Tube82.1USD tube
Clobetasol 17-prop powder70.74USD g
Clobetasol Propionate 0.05% Cream 60 gm Tube64.15USD tube
Clobetasol Propionate 0.05% Ointment 60 gm Tube64.15USD tube
Clobetasol Propionate 0.05% Gel 30 gm Tube51.66USD tube
Clobetasol Propionate 0.05% Ointment 45 gm Tube50.56USD tube
Clobetasol Propionate 0.05% Cream 45 gm Tube48.57USD tube
Temovate 0.05% Gel 15 gm Tube47.38USD tube
Temovate E 0.05% Cream 15 gm Tube44.9USD tube
Clobetasol Propionate 0.05% Solution 50ml Bottle41.18USD bottle
Clobetasol Propionate 0.05% Cream 30 gm Tube34.79USD tube
Clobetasol Propionate 0.05% Ointment 30 gm Tube34.79USD tube
Clobetasol Propionate 0.05% Gel 15 gm Tube28.86USD tube
Clobetasol Propionate 0.05% Solution 25ml Bottle26.99USD bottle
Clobetasol Propionate 0.05% Cream 15 gm Tube24.94USD tube
Clobetasol Propionate 0.05% Ointment 15 gm Tube24.1USD tube
Olux 0.05% foam6.77USD g
Olux-e 0.05% foam5.9USD g
Clobex 0.05% topical lotion4.58USD ml
Temovate emollient 0.05% crm3.75USD g
Olux-olux-e complete pack3.43USD g
Temovate 0.05% cream3.29USD g
Cormax 0.05% cream2.06USD g
Embeline 0.05% cream1.86USD g
Clobetasol 0.05% cream1.43USD g
Dermovate 0.05 % Cream0.72USD g
Dermovate 0.05 % Ointment0.72USD g
Dermovate 0.05 % Lotion0.63USD g
Mylan-Clobetasol 0.05 % Cream0.38USD g
Mylan-Clobetasol 0.05 % Ointment0.38USD g
Novo-Clobetasol 0.05 % Cream0.38USD g
Novo-Clobetasol 0.05 % Ointment0.38USD g
Pms-Clobetasol 0.05 % Cream0.38USD g
Pms-Clobetasol 0.05 % Ointment0.38USD g
Ratio-Clobetasol 0.05 % Cream0.38USD g
Ratio-Clobetasol 0.05 % Ointment0.38USD g
Taro-Clobetasol 0.05 % Cream0.38USD g
Taro-Clobetasol 0.05 % Ointment0.38USD g
Mylan-Clobetasol 0.05 % Lotion0.33USD g
Pms-Clobetasol 0.05 % Lotion0.33USD g
Ratio-Clobetasol 0.05 % Lotion0.33USD g
Taro-Clobetasol 0.05 % Lotion0.33USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2333869No2009-01-062019-09-08Canada
CA2333427No2007-01-092019-06-17Canada
US6126920No1996-03-012016-03-01Us
US8460641No2008-11-052028-11-05Us
US8962000No2005-08-312025-08-31Us
US6730288No1999-09-082019-09-08Us
US7029659No1999-09-082019-09-08Us
US6106848No1997-09-222017-09-22Us
US7700081No2002-01-032022-01-03Us
US8066975No1999-06-172019-06-17Us
US7316810No1999-06-172019-06-17Us
US8066976No1999-06-172019-06-17Us
US5990100No1998-03-242018-03-24Us
US5972920No1998-02-122018-02-12Us
US9855334No2015-03-112035-03-11Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)226Elks, J., Phillipps, G.H. and May, P.J.; US. Patent 3,721,687; March 20, 1973; assigned to Glaxo Laboratories Limited, England.
water solubility3.86 mg/LNot Available
logP3.50SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.00413 mg/mLALOGPS
logP3.49ALOGPS
logP4.18ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)13.63ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area80.67 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity119.32 m3·mol-1ChemAxon
Polarizability48.28 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9814
Caco-2 permeable+0.812
P-glycoprotein substrateSubstrate0.7852
P-glycoprotein inhibitor INon-inhibitor0.7375
P-glycoprotein inhibitor IINon-inhibitor0.7683
Renal organic cation transporterNon-inhibitor0.7883
CYP450 2C9 substrateNon-substrate0.8533
CYP450 2D6 substrateNon-substrate0.9077
CYP450 3A4 substrateSubstrate0.7967
CYP450 1A2 substrateNon-inhibitor0.9412
CYP450 2C9 inhibitorNon-inhibitor0.8713
CYP450 2D6 inhibitorNon-inhibitor0.8327
CYP450 2C19 inhibitorNon-inhibitor0.9126
CYP450 3A4 inhibitorNon-inhibitor0.5411
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9129
Ames testNon AMES toxic0.8848
CarcinogenicityNon-carcinogens0.935
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.1435 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9314
hERG inhibition (predictor II)Non-inhibitor0.5569
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a6r-0596000000-b19d97ac39952d18b68e
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03mj-3971000000-8f42562c23aaf5e5d240

Taxonomy

Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Steroid esters / 20-oxosteroids / 11-beta-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Alpha-acyloxy ketones / Alpha-chloroketones / Fluorohydrins / Cyclic ketones
show 10 more
Substituents
Progestogin-skeleton / Steroid ester / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 11-hydroxysteroid / 11-beta-hydroxysteroid / Oxosteroid / 9-halo-steroid / Halo-steroid
show 27 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
11beta-hydroxy steroid, glucocorticoid, 20-oxo steroid, fluorinated steroid, 3-oxo-Delta(1),Delta(4)-steroid, chlorinated steroid (CHEBI:31414)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Fitzgerald P, O'Brien SM, Scully P, Rijkers K, Scott LV, Dinan TG: Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression. Psychol Med. 2006 Jan;36(1):37-43. Epub 2005 Oct 28. [PubMed:16255837]
  2. Hofmann TG, Hehner SP, Bacher S, Droge W, Schmitz ML: Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF-kappaB-dependent transcription. FEBS Lett. 1998 Dec 28;441(3):441-6. [PubMed:9891987]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on April 17, 2018 01:03